These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
122 related items for PubMed ID: 2504917
1. Short term effects of low dose methotrexate on the acute phase reaction in patients with rheumatoid arthritis. Segal R, Caspi D, Tishler M, Wigler I, Yaron M. J Rheumatol; 1989 Jul; 16(7):914-7. PubMed ID: 2504917 [Abstract] [Full Text] [Related]
2. Short-term effects of the TNFalpha antagonist infliximab on the acute phase reaction and activities of daily life in patients with rheumatoid arthritis. Arvidson NG, Larsen A, Aaseth J, Larsson A. Scand J Clin Lab Invest; 2007 Jul; 67(3):337-42. PubMed ID: 17454848 [Abstract] [Full Text] [Related]
3. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis. Posthumus MD, Limburg PC, Westra J, van Leeuwen MA, van Rijswijk MH. J Rheumatol; 2002 May; 29(5):883-9. PubMed ID: 12022344 [Abstract] [Full Text] [Related]
4. Equivalence of the acute phase reactants C-reactive protein, plasma viscosity, and Westergren erythrocyte sedimentation rate when used to calculate American College of Rheumatology 20% improvement criteria or the Disease Activity Score in patients with early rheumatoid arthritis. Western Consortium of Practicing Rheumatologists. Paulus HE, Ramos B, Wong WK, Ahmed A, Bulpitt K, Park G, Sterz M, Clements P. J Rheumatol; 1999 Nov; 26(11):2324-31. PubMed ID: 10555885 [Abstract] [Full Text] [Related]
6. Effect of low dose methotrexate on markers of bone metabolism in patients with rheumatoid arthritis. El Miedany YM, Abubakr IH, El Baddini M. J Rheumatol; 1998 Nov; 25(11):2083-7. PubMed ID: 9818648 [Abstract] [Full Text] [Related]
12. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone. O'Dell JR, Elliott JR, Mallek JA, Mikuls TR, Weaver CA, Glickstein S, Blakely KM, Hausch R, Leff RD. Arthritis Rheum; 2006 Feb; 54(2):621-7. PubMed ID: 16447240 [Abstract] [Full Text] [Related]
13. Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis. Klimiuk PA, Fiedorczyk M, Sierakowski S, Chwiecko J. Scand J Rheumatol; 2007 Feb; 36(5):345-50. PubMed ID: 17963163 [Abstract] [Full Text] [Related]
14. Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. Mallya RK, de Beer FC, Berry H, Hamilton ED, Mace BE, Pepys MB. J Rheumatol; 1982 Feb; 9(2):224-8. PubMed ID: 7097681 [Abstract] [Full Text] [Related]
16. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M. Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087 [Abstract] [Full Text] [Related]
17. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V. Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477 [Abstract] [Full Text] [Related]